Discussion of a Phase III trial evaluating the efficacy and safety of idelalisib

Phase III study evaluating the efficacy and safety of IDELA for previously treated CLLПодробнее

Phase III study evaluating the efficacy and safety of IDELA for previously treated CLLПодробнее

Results of Phase II trial to assess the efficacy and safety of idelalisibПодробнее

Updated analysis of Phase III trial of idelalisib combined with bendamustine and rituximab in CLLПодробнее

Dr. Furman on the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLLПодробнее

Safety/Efficacy of Idelalisib in Follicular LymphomaПодробнее

Idelalisib in Chronic Lymphocytic LeukemiaПодробнее

CLL: Long-term updates on ibrutinib and idelalisibПодробнее

Approaches to overcome side effects of idelalisib for follicular lymphomaПодробнее

Dr. Ian Flinn Discusses the Efficacy of IPI-145 in CLLПодробнее

Phase 2 Study Evaluating the Efficacy and Safety of ParsaclisibПодробнее

Tirabrutinib with idelalisib or entospletinib +/- obinutuzumab in R/R CLLПодробнее

Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLLПодробнее

Second Interim Phase 3 Study of Idelalisib /Rituximab for Relapsed Chronic Lymphocytic LeukemiaПодробнее

Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLLПодробнее

Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLLПодробнее

Understanding the Trial With Idelalisib and RituximabПодробнее

Dr. Jeffrey Jones on Efficacy of Idelalisib/Ofatumumab Combination in CLLПодробнее

Dr. Jain on the Combination of Idelalisib and Rituximab for Older Patients With CLLПодробнее